Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy

Journal of Experimental Medicine

Volumn 186, Issue 5, 1997, Pages 645-653

  Speiser, Daniel E ^a,d   Miranda, Renata ^a   Zakarian, Arsen ^a   Bachmann, Martin F ^a   McKall Faienza, Kim ^a   Odermatt, Bernhard ^b   Hanahan, Douglas ^c   Zinkernagel, Rolf M ^b   Ohashi, Pamela S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ETIOLOGY; IMMUNOGENICITY; INSULINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, POLYOMAVIRUS TRANSFORMING; AUTOIMMUNE DISEASES; BLOOD GLUCOSE; CROSSES, GENETIC; FEMALE; GENES, MHC CLASS I; GLYCOPROTEINS; HYPOGLYCEMIA; IMMUNOTHERAPY; INSULINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RATS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 0030848578     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.5.645     Document Type: Article

References (43)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
2. Slingluff, C.L., Jr., D.F. Hunt, and V.H. Engelhard. 1994. Direct analysis of tumor-associated peptide antigens. Curr. Opiti. Immunol. 6:733-740.
3. Melief, C.J.M., and W.M. Kast. 1994. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145:167-177.
4. Hellström, K.E., I. Hellström, and L. Chen. 1994. Can costimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145:123-145.
5. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722-727.
6. Ye, X., J. McCarrick, L. Jewett, and B.B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA. 91:3916-3920.
7. Cromme, F.V., J. Airey, M.-T. Heemels, H.L. Ploegh, P.J. Keating, P.L. Stern, C.J.L.M. Meijer, and J.M.M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335-340.
8. Cohen, E.P., and T.S. Kim. 1994. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:419-428.
9. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J.J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, and P.L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:89-95.
10. Onrust, S.V., P.M. Hartl, S.D. Rosen, and D. Hanahan. 1996. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97:54-64.
11. Boon, T., and O. Kellermann. 1977. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl. Acad. Sci. USA. 74:272-275.
12. Boon, T., and A. Van Pel. 1978. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA. 75: 1519-1523.
13. Chen, L., S. Ashe, W.A. Brady, I. Hellström, K.E. Hellström, J.A. Ledbetter, P. McGowan, and P.S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093-1102.
14. + T cells by B7-transfected melanoma cells. Science (Wash. DC). 259:368-370.
15. Huang, A.Y.C., A.T. Bruce, D.M. Pardoll, and H.I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769-776.
16. Förster, I., R. Hirose, J.M. Arbeit, B.E. Clausen, and D. Hanahan. 1995. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic β cell neo-antigen. Immunity. 2:573-585.
17. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
18. Nanda, N.K., and E.E. Sercarz. 1995. Induction of anti-self-immunity to cure cancer. Cell. 82:13-17.
19. Van Pel, A., P. van der Bruggen, P.G. Coulie, V.G. Brichard, B. Lethe, B. Van den Eynde, C. Uyttenhove, J.-C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229-250.
20. Livingston, D.M. 1992. Functional analysis of the retinoblastoma gene product and of RB-SV40 T antigen complexes. In Tumor Suppressor Genes, the Cell Cycle and Cancer. A.J. Levine and L.M. Franks, editors. Imperial Cancer Research Fund, Cold Spring Harbor, NY. 153-160.
21. Ludlow, J.W. 1993. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB (Fed. Am. Soc. Exp. Biol.) J. 7:866-871.
22. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/ simian virus 40 oncogenes. Nature (Lond.). 315:115-122.
23. Adams, T.E., S. Alpert, and D. Hanahan. 1987. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells. Nature (Lond.). 325:223-228.
24. Ohashi, P.S., S. Oehen, K. Bürki, H. Pircher, C.T. Ohashi, B. Odermatt, B. Malissen, R. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65: 305-317.
25. Lehmann-Grube, F. 1971. Lymphocytic choriomeningitis virus. Virol. Monogr. 10:1-173.
26. Moskophidis, D., U. Assmann-Wischer, M.M. Simon, and F. Lehmann-Grube. 1987. The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection. Eur. J. Immunol. 17:937-942.
27. Pircher, H., K. Bürki, R. Lang, H. Hengartner, and R. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (Lond.). 342:559-561.
28. Springer, T.A. 1980. Cell-surface differentiation in the mouse. In Monoclonal Antibodies. R.H. Kennett, T.J. McKearn, and K.B. Bechtol, editors. Plenum Press, New York. 185-217.
29. Cobbold, S.P., A. Jayasuriya, A. Nash, T.D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.). 312:548-551.
30. Klavinskis, L.S., J.L. Whitton, E. Joly, and M.B.A. Oldstone. 1990. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology. 178:393-400.
31. von Herrath, M.G., J. Dockter, and M.B.A. Oldstone. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity. 1:231-242.
32. Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-782.
33. Klein, E., and G. Klein. 1964. Antigenic properties of lymphomas induced by the Moloney agent. J. Natl. Cancer Inst. 32:547-565.
34. Kripke, M.L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 53:1333-1336.
35. Zinkernagel, R.M., H. Pircher, P.S. Ohashi, S. Oehen, B. Odermatt, T.W. Mak, H. Arnheiter, K. Bürki, and H. Hengartner. 1991. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol. Rev. 122:133-171.
36. Kündig, T.M., M.F. Bachmann, C. DiPaolo, J.J.L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kühlcke, P.S. Ohashi, H. Hengartner, and R.M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid tissues. Science (Wash. DC). 268:1343-1347.
37. Naughton, G.K., M. Eisinger, and J.C. Bystryn. 1983. Autoantibodies to normal human melanocytes in vitiligo. J. Exp. Med. 158:246-251.
38. Song, Y.-H., E. Conner, Y. Li, B. Zorovich, P. Balducci, and N. Maclaren. 1994. The role of tyrosinase in autoimmune vitiligo. Lancet. 344:1049-1052.
39. Visseren, M.J.W., A. van Elsas, E.I.H. van der Voort, M.E. Ressing, W.M. Kast, P.I. Schrier, and C.J.M. Melief. 1995. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154:3991-3998.
40. Nordlund, J.J., J.M. Kirkwood, B.M. Forget, G. Milton, D.M. Albert, and A.B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Derm. 9:689-695.
41. Kawakaini, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yanelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
42. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
43. Hu, J., W. Kindsvogel, S. Busby, M.C. Bailey, Y.Y. Shi, and P.D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177:1681-1690.